Skip to main content
Article thumbnail
Location of Repository

t10c12 Conjugated Linoleic Acid Suppresses HER2 Protein and Enhances Apoptosis in SKBr3 Breast Cancer Cells: Possible Role of COX2

By Margaret Flowers and Patricia A. Thompson
Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:2671134
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2005). 10t,12c-conjugated linoleic acid inhibits lipopolysaccharide-induced cyclooxygenase expression in vitro and in vivo.
    2. (1999). Activators and target genes of Rel/NF-kappaB transcription factors.
    3. (2008). Advances in the treatment of breast cancer.
    4. (2002). An enriched mixture of trans-10,cis-12-CLA inhibits linoleic acid metabolism and PGE2 synthesis in MDA-MB-231 cells.
    5. (2000). Antiinflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase.
    6. (2003). Apoptosis caused by chemotherapeutic inhibition of nuclear factor-kappaB activation.
    7. (2008). Bioactive dietary long-chain fatty acids: emerging mechanisms of action.
    8. (2002). Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer.
    9. (2007). cis-9,trans-11-conjugated linoleic acid down-regulates phorbol ester-induced NF-kappaB activation and subsequent COX-2 expression in hairless mouse skin by targeting IkappaB kinase and PI3K-Akt.
    10. (2005). Congulated linoleic acid decreases cellular proliferation and inhibits nuclear factor-[kappa]B and activator protein 1 activation in PC3 cancerous prostate epithelial cells.
    11. (2006). Conjugated linoleic acid attenuates cyclooxygenase-2 transcriptional activity via an anti-AP-1 mechanism in MCF-7 breast cancer cells.
    12. (2003). Conjugated linoleic acid inhibits cell proliferation and ErbB3 signaling in HT-29 human colon cell line.
    13. (2003). Conjugated linoleic acid inhibits cell proliferation through a p53-dependent mechanism: effects on the expression of G1-restriction points in breast and colon cancer cells.
    14. (1999). Conjugated linoleic acid inhibits proliferation and induces apoptosis of normal rat mammary epithelial cells in primary culture.
    15. (2007). Conjugated linoleic acid isomers and cancer.
    16. (2002). Conjugated linoleic acids (CLAs) regulate the expression of key apoptotic genes in human breast cancer cells.
    17. (2008). Conjugated linoleic acids produced by Lactobacillus dissociates IKK-gamma and Hsp90 complex in Helicobacter pylori-infected gastric epithelial cells.
    18. (2004). Conjugated linoleic acids: are they beneficial or detrimental to health?
    19. (1999). Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen.
    20. (1997). Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth.
    21. (2002). Constitutive activation of NF-kappaB in Ki-ras-transformed prostate epithelial cells.
    22. (2004). Contribution of conjugated linoleic acid to the suppression of inflammatory responses through the regulation of the NF-kappaB pathway.
    23. (1993). Crosscoupling of the NF-kappa B p65 and Fos/Jun transcription factors produces potentiated biological function.
    24. (2001). Differential Sensitivity of Breast Cancer Cells to Tumor Necrosis Factor-[alpha]:
    25. (1996). Elevated serum levels of p105(erbB-2) in patients with advanced-stage prostatic adenocarcinoma.
    26. (2007). Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer.
    27. (2002). Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
    28. (2007). Esteva FJ
    29. (2006). HER-2 and NF-kappaB as the targets for therapy-resistant breast cancer.
    30. (2000). HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway.
    31. (2001). Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN.
    32. (2007). IkappaB kinase alpha kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells.
    33. (2006). Induction of apoptosis and inhibition of NF-kappaB activation in human prostate cancer cells by the cis-9, trans-11 but not the trans-10, cis-12 isomer of conjugated linoleic acid.
    34. (2002). Inhibition of Angiogenesis by the Cancer Chemopreventive Agent Conjugated Linoleic Acid.
    35. (2005). Inhibition of colon cancer cell proliferation by the dietary compound conjugated linoleic acid is mediated by the CDK inhibitor p21CIP1/WAF1.
    36. (2001). Leukemia stem cells and constitutive activation of NF-kappaB.
    37. (2006). Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer.
    38. (2007). Membrane-type 1 matrix metalloproteinase is regulated by sp1 through the differential activation of AKT, JNK, and ERK pathways in human prostate tumor cells.
    39. (2001). Modulation of arachidonic acid distribution by conjugated linoleic acid isomers and linoleic acid in MCF-7 and SW480 cancer cells.
    40. (2007). Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells.
    41. (2004). NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis.
    42. (2007). NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation.
    43. (2008). Nuclear factor-kappaB activation: from bench to bedside. Exp Biol Med (Maywood)
    44. (2005). Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs.
    45. (2004). Nuclear factor-kappaB: the enemy within.
    46. (2005). Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin) in breast cancer cells with Her-2/neu oncogene amplification.
    47. (2000). Overexpression of ErbB2 in cancer and ErbB2-targeting strategies.
    48. (2004). Phase II Study of Celecoxib and Trastuzumab in Metastatic Breast Cancer Patients Who Have Progressed after Prior Trastuzumab-Based Treatments.
    49. (2008). Progesterone receptor inhibits aromatase and inflammatory response pathways in breast cancer cells via ligand-dependent and ligand-independent mechanisms.
    50. (2006). Regulation and function of IKK and IKK-related kinases. Sci STKE
    51. (2004). Regulation of HER-2 oncogene expression by cyclooxygenase-2 and prostaglandin E2.
    52. (2002). Retinoids and carnosol suppress cyclooxygenase-2 transcription by CREB-binding protein/p300-dependent and -independent mechanisms.
    53. (2002). Suppression of cyclooxygenase-2 and inducible nitric oxide synthase expression by conjugated linoleic acid in murine macrophages.
    54. (1996). Suppression of TNF-alpha-induced apoptosis by NF-kappaB.
    55. (2008). Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells. Ann Oncol.
    56. (2008). t10,c12-Conjugated linoleic acid stimulates mammary tumor progression in Her2/ErbB2 mice through activation of both proliferative and survival pathways.
    57. (2001). Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth.
    58. (2004). The achilles heel of ErbB-2/ HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention.
    59. (1998). The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.
    60. (2001). The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers.
    61. (2000). The RelA NF-kappaB subunit and the aryl hydrocarbon receptor (AhR) cooperate to transactivate the c-myc promoter in mammary cells.
    62. (2007). The t10,c12 isomer of conjugated linoleic acid stimulates mammary tumorigenesis in transgenic mice over-expressing erbB2 in the mammary epithelium.
    63. (2005). Trans-10,cis-12, not cis-9,trans-11, conjugated linoleic acid decreases ErbB3 expression in HT-29 human colon cancer cells.
    64. (2000). Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells.
    65. (2007). Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.
    66. (2006). What are cyclooxygenases and lipoxygenases doing in the driver’s seat of carcinogenesis?

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.